Safety, Tolerability, and Pharmacokinetics of ID119031166M With the Exploration of Pharmacodynamic Effects

Inclusion Criteria: * Must be Caucasian (White American of European or Latin American descent). * Healthy participants of Japanese origin are allowed up to 50% in each MAD cohort. * Body mass index (BMI) within the range of 18.5 to 30 kg/m\^2 (inclusive) at the time of Screening. * No congenital or chronic diseases that require treatment and without pathologic symptoms or signs on medical examinations. * Participants with normal renal function. * Women are eligible to participate if not pregnant, not breastfeeding. Male subjects should be willing to use 'highly effective' or 'applicable' contraceptive methods. Exclusion Criteria: * Currently have an acute disease with active symptoms. * History of melanoma or other skin issues (including, but not limited to pre-cancerous areas, atopic dermatitis, psoriasis, rosacea, excessive moles etc.). * History of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, musculoskeletal, or cardiovascular disease and/or arrhythmias. * History of clinically significant hypersensitivity reaction to any drugs or additives. * History of any gastrointestinal disease. * History of substance use disorder including history of drug abuse disorder or history of alcohol use disorder, or tobacco use disorder or excessive caffeine intake. * Evidence of moderate or excessive alcohol consumption. * Tested positive in viral serology tests (hepatitis B virus \[HBV\], hepatitis C virus \[HCV\], and human immunodeficiency virus \[HIV\]). * Known family history or known presence of long QT syndrome. * A history of hypokalemia. * Use of concomitant medicines that prolong QT/QTc (QT Interval Corrected for Heart Rate). * History of active viral hepatitis (hepatitis A, B, C, and E), or autoimmune hepatitis. * History of Multiple Endocrine Neoplasia type 2. * Solid organ transplantation, except corneal transplants. * History or presence of neutropenia which is defined as absolute neutrophil count (ANC) \< 1.5 at Screening and admission. * Participants with a microalbuminuria. * Hemoglobin levels below 12.0 g/dL at Screening or Baseline. * White Blood Cell levels below 3.5 × 109/L at Screening or Baseline. * Platelet count \< 150,000/µL, international normalized ratio (INR) \> 1.5, albumin \< 3.5 g/dL